Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis greenmarketreport Views: 293

-

The Daily Hit is a recap of the top cannabis business stories for June 9, 2022.

ON THE SITE

Cannabis Tech Company Canix Raises $10M

Cannabis seed-to-sale platform company Canix raised $10 million in funding from venture capitalists.  Canix launched in 2019 from Y Combinator and, in 2020, won TechCruch Disrupt Startup Battlefield. Both founders were also featured in Forbes 30 Under 30. Since then, Canix has expanded to serve 2,300 licenses across 15+ states and 6 countries. “This is a huge milestone for us. Our goal has always been to help businesses in the cannabis industry thrive,” said Stacey Hronowski, Co-Founder and CEO of Canix. Read more here.

Neptune Wellness is Selling its Canadian Cannabis Business

Neptune Wellness Solutions Inc.  (NASDAQ: NEPT) (TSX: NEPT) announced the launch of a new Consumer Packaged Goods (CPG) focused strategic plan to reduce costs, improve the company’s path to profitability and enhance current shareholder value. Neptune is also selling its Canadian cannabis businesses. Read more here.

4Front Names Keith Adams as New CFO

4Front Ventures Corp.(CSE: FFNT) (OTCQX: FFNTF) has made several C-suite changes including a new Chief Financial Officer, Executive Vice President, General Counsel, President of California Operations, and two additional Board members. Andrew Thut, who served as an interim chief financial officer, will remain in his original capacity as a chief investment officer for the 4Front. Read more here.

IN OTHER NEWS

TILT Holdings Inc.

TILT Holdings Inc. (NEO:TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, today announces the results of the annual general and special meeting of shareholders of TILT held virtually on Thursday, June 9, 2022. Read more here.

Allied Corp.

Allied Corp. (OTCQB: ALID) announced the execution of the agreement that was announced in the April 27 press release announcing the signing of a forward purchase agreement with a distributor for a specialty medical care hospital, based out of Sao Paulo, Brazil. Read more here.

Bia Diagnostics

Bia Diagnostics, an ISO 17025 accredited laboratory and global leader in food and nutraceutical analysis since 2007, has become the first analytical lab in the state of Vermont to be licensed for adult use cannabis, and is currently accepting samples at their 480 Hercules Drive, Colchester, Vermont location. Read more here.

The Daily Hit: June 9, 2022 on Green Market Report.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.